Tokyo, Japan

Daishiro Miura




Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 18(Granted Patents)


Location History:

  • Hino, JP (2003)
  • Tokyo, JP (2007 - 2015)

Company Filing History:


Years Active: 2003-2015

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Daishiro Miura: Innovator in Pharmaceutical Chemistry

Introduction

Daishiro Miura is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for medical treatments. With a total of 3 patents to his name, Miura's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Miura's latest patents include a compound effective for the treatment of Paget's disease of bone or hypercalcemia. This compound is represented by a specific formula that includes various chemical groups. Additionally, he has developed a method for testing myelotoxicity using flow cytometry. This innovative approach addresses the low test efficiency and accuracy of conventional methods by identifying hematopoietic stem cells and blood cells at different differentiation stages in bone marrow.

Career Highlights

Throughout his career, Daishiro Miura has worked with prominent companies such as Teijin Limited and Teijin Pharma Limited. His experience in these organizations has allowed him to refine his expertise in pharmaceutical research and development.

Collaborations

Miura has collaborated with notable colleagues, including Kiyoyuki Sakon and Yoshimitsu Naniwa. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Daishiro Miura's contributions to pharmaceutical chemistry through his innovative patents demonstrate his commitment to improving medical treatments. His work continues to influence the field and offers promising solutions for various health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…